We have evaluated the feasibility of administering human recombinant interferon α2 and human natural interferon β via the intradermal route with an air-pressure injector in the rabbit model. This is the first report showing pharmacokinetic parameters after intradermal administration of interferon. The prolonged permanence of circulating interferon α2 and its excellent bioavailability make this route an attractive one to be tested in patients because it may increase the therapeutic index of IFN. On the other hand. this route seems less practical for IFN β for reasons probably connected with inactivation and/or scarce absorption of this drug from the skin.

Bocci, V., Muscettola, M.M., Naldini, A. (1986). The lymphatic route. IV.Pharmacokinetics of human recombinant interferon alpha2 and natural interferon beta administered intradermally in rabbits. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 32(2-3), 103-110 [10.1016/0378-5173(86)90168-7].

The lymphatic route. IV.Pharmacokinetics of human recombinant interferon alpha2 and natural interferon beta administered intradermally in rabbits

Bocci, V.;Muscettola, M. M.;Naldini, A.
1986-01-01

Abstract

We have evaluated the feasibility of administering human recombinant interferon α2 and human natural interferon β via the intradermal route with an air-pressure injector in the rabbit model. This is the first report showing pharmacokinetic parameters after intradermal administration of interferon. The prolonged permanence of circulating interferon α2 and its excellent bioavailability make this route an attractive one to be tested in patients because it may increase the therapeutic index of IFN. On the other hand. this route seems less practical for IFN β for reasons probably connected with inactivation and/or scarce absorption of this drug from the skin.
1986
Bocci, V., Muscettola, M.M., Naldini, A. (1986). The lymphatic route. IV.Pharmacokinetics of human recombinant interferon alpha2 and natural interferon beta administered intradermally in rabbits. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 32(2-3), 103-110 [10.1016/0378-5173(86)90168-7].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/26891
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo